La Jolla Pharmaceutical Company (LJPC) Financial Statements (2024 and earlier)

Company Profile

Business Address 201 JONES ROAD, SUITE 400
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 46,66821,22187,820172,60490,91565,726
Cash and cash equivalents 46,66821,22187,820172,60490,91565,726
Receivables 8,6105,8342,9601,381  
Inventory, net of allowances, customer advances and progress billings 6,2816,0132,2112,020  
Inventory 6,2816,0132,2112,020  
Prepaid expense 473505    
Other undisclosed current assets 5,2832,8834,4675,1113,1471,705
Total current assets: 67,31536,45697,458181,11694,06267,431
Noncurrent Assets
Operating lease, right-of-use asset 318536 
Property, plant and equipment 11321518,38922,26724,5683,145
Intangible assets, net (including goodwill) 33,44434,996    
Goodwill 20,12320,123    
Intangible assets, net (excluding goodwill) 13,32114,873    
Restricted cash and investments 4040909909909 
Other undisclosed noncurrent assets   15,491  219
Total noncurrent assets: 33,91535,78734,78923,17625,4773,364
TOTAL ASSETS: 101,23072,243132,247204,292119,53970,795
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 7,14412,13421,82129,06917,1829,758
Employee-related liabilities  2,8788,3327,5094,9952,077
Accounts payable 2,2782,7624,1778,57211,4846,652
Accrued liabilities 4,8666,4949,31212,9887031,029
Deferred revenue 2,849  
Deferred rent credit    1,370
Deferred revenue and credits1,370 
Other undisclosed current liabilities 7,6422042,766   
Total current liabilities: 17,63512,33824,58730,43918,5529,758
Noncurrent Liabilities
Long-term debt and lease obligation: 164332    
Liabilities, other than long-term debt 1,0764,11212,79013,60912,785 
Deferred revenue and credits12,785 
Deferred rent credit    13,609
Other liabilities 1,0764,11212,790   
Operating lease, liability 164332 
Other undisclosed noncurrent liabilities 149,093143,548150,860124,323  
Total noncurrent liabilities: 150,333147,992163,650137,93212,785 
Total liabilities: 167,968160,330188,237168,37131,3379,758
Equity
Equity, attributable to parent, including: (66,738)(88,087)(55,990)35,92188,20261,037
Common stock 333322
Additional paid in capital 986,445984,756977,432950,258803,071661,103
Accumulated deficit (1,057,092)(1,076,752)(1,037,331)(920,983)(721,514)(606,711)
Other undisclosed equity, attributable to parent 3,9063,9063,9066,6436,6436,643
Total equity: (66,738)(88,087)(55,990)35,92188,20261,037
TOTAL LIABILITIES AND EQUITY: 101,23072,243132,247204,292119,53970,795

Income Statement (P&L) ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 75,72033,41923,05410,056 616
Revenue, net 616
Cost of revenue (11,937)(7,819)(2,392)(1,643)(1,600)(521)
Cost of goods and services sold (850)(7,819)(2,392)(1,643)(1,600)(521)
Gross profit: 63,78325,60020,6628,413(1,600)95
Operating expenses (41,952)(61,438)(130,463)(202,464)(115,427)(78,988)
Other undisclosed operating income     1,600521
Operating income (loss): 21,831(35,838)(109,801)(194,051)(115,427)(78,372)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 733(46) (5,418)624187
Interest and debt expense (10,458)(10,051)(10,774)(7,303)  
Income (loss) from continuing operations before equity method investments, income taxes: 12,106(45,935)(120,575)(206,772)(114,803)(78,185)
Other undisclosed income from continuing operations before income taxes 7,603     
Income (loss) from continuing operations before income taxes: 19,709(45,935)(120,575)(206,772)(114,803)(78,185)
Income tax expense (49)     
Income (loss) from continuing operations: 19,660(45,935)(120,575)(206,772)(114,803)(78,185)
Income (loss) before gain (loss) on sale of properties:19,660(45,935)(120,575)(206,772)(114,803)(78,185)
Net income (loss): 19,660(45,935)(120,575)(206,772)(114,803)(78,185)
Other undisclosed net income attributable to parent  6,5144,0677,303  
Net income (loss) available to common stockholders, diluted: 19,660(39,421)(116,508)(199,469)(114,803)(78,185)

Comprehensive Income ($ in thousands)

6/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss): 19,660(45,935)(120,575)(206,772)(114,803)(78,185)
Comprehensive income (loss), net of tax, attributable to parent: 19,660(45,935)(120,575)(206,772)(114,803)(78,185)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: